-transparent.png){kind=logo}
Fifty women with refractory obesity received phentermine resinate. Seven were withdrawn because of side-effects: three developed severe headaches, one each hypertension, depressive symptoms, breathlessness and palpitations with irritability. The mean weight loss in the 34 who completed the 20-week study was 6.4 kg. Nine lost 10 kg or more. Sustained appetite suppression was related to weight loss. Plasma phentermine concentrations did not correlate with the severity of the obesity problem, the degree of subjective anorexia or with weight loss. Poor initial response to standard dosage of phentermine is unlikely to improve with higher dosage. The individual's response to phentermine is unpredictable and appears to relate to factors other than the plasma drug concentration.
A Douglas, and
J G Douglas, and
C E Robertson, and
J F Munro
November 1977,
British medical journal,
A Douglas, and
J G Douglas, and
C E Robertson, and
J F Munro
January 1982,
International journal of obesity,
A Douglas, and
J G Douglas, and
C E Robertson, and
J F Munro
October 2002,
The New England journal of medicine,
A Douglas, and
J G Douglas, and
C E Robertson, and
J F Munro
October 2002,
The New England journal of medicine,
A Douglas, and
J G Douglas, and
C E Robertson, and
J F Munro
October 2002,
The New England journal of medicine,
A Douglas, and
J G Douglas, and
C E Robertson, and
J F Munro
August 1997,
The Nurse practitioner,
A Douglas, and
J G Douglas, and
C E Robertson, and
J F Munro
December 2016,
The Medical letter on drugs and therapeutics,
A Douglas, and
J G Douglas, and
C E Robertson, and
J F Munro
December 2014,
Diabetes care,
A Douglas, and
J G Douglas, and
C E Robertson, and
J F Munro
August 2013,
P & T : a peer-reviewed journal for formulary management,
A Douglas, and
J G Douglas, and
C E Robertson, and
J F Munro
February 2024,
The primary care companion for CNS disorders,
